Francesco Raspagliesi

Author

Fondazione IRCCS Istituto Nazionale dei Tumori ORCID

Also Known As

C Piazza, F RASPAGLIESI, F Raspagliesi, F. RASPAGLIESI, F. Raspagliesi, Fernando Roldan, Francesco RASPAGLIESI, Francesco Raspagliesi, Giovanni Scambia, Jvan Casarin

752

Publications

21.9K

Citations

H-Index

131

Concepts

All Affiliations

Fondazione IRCCS Istituto Nazionale dei Tumori Istituti di Ricovero e Cura a Carattere Scientifico Agostino Gemelli University Polyclinic Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"Centro di Riferimento Oncologico

About

Francesco Raspagliesi is an author at Fondazione IRCCS Istituto Nazionale dei Tumori specializing in medicine, obstetrics, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	52	132	9.5K
2	Public Health	24	37	2.7K
3	Health Sciences	13	15	821
4	Engineering	5	5	230
5	Natural Sciences	1	1	12

Francesco Raspagliesi

267

Publications

17.4K

Citations

H-Index

Page 1

	Year	Citations
Systematic Pelvic Lymphadenectomy vs No Lymphadenectomy in Early-Stage Endometrial Carcinoma: Randomized Clinical Trial Pierluigi Benedetti Panici, S. Basile, F. Maneschi, JNCI Journal of the National Cancer Institute	2008	1.5K
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study Ursula A. Matulonis, Ronnie Shapira‐Frommer, Alessandro D. Santin, Annals of Oncology Antitumor ActivityOncologyMedicineGynecologyImmune Checkpoint Inhibitor	2019	786
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer Mansoor Raza Mirza, Dana M. Chase, Brian M. Slomovitz, New England Journal of Medicine	2023	718
A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms Philipp Harter, Jalid Sehouli, Domenica Lorusso, New England Journal of Medicine	2019	571
The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer David Cibula, Richard Pötter, François Planchamp, International Journal of Gynecological Cancer Cervical Cancer ScreeningCervical Cancer ManagementCervical CancerCervical HealthGynecological Surgery	2018	470
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial Sandro Pignata, Giovanni Scambia, Dionyssios Katsaros, The Lancet Oncology Advanced Ovarian CancerMedicineMetronomic TherapyGynecologyWeek Versus	2014	386
The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer David Cibula, Richard Pötter, François Planchamp, Radiotherapy and Oncology Cervical Cancer ScreeningCervical Cancer ManagementCervical CancerCervical HealthGynecological Surgery	2018	382
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study Robert L. Coleman, Domenica Lorusso, Christine Gennigens, The Lancet Oncology Tisotumab VedotinCervical CancerMetastatic Cervical CancerMedicineClinical Trials	2021	367
Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial Bradley J. Monk, Andrés Poveda, Ignace Vergote, The Lancet Oncology OncologyPlacebo-controlled Phase 3Metronomic TherapyClinical TrialsGynecology	2014	304
SUCCOR study: an international European cohort observational study comparing minimally invasive surgery versus open abdominal radical hysterectomy in patients with stage IB1 cervical cancer Luis Chiva, Vanna Zanagnolo, Denis Querleu, International Journal of Gynecological Cancer	2020	284

Page 1